Vanda Pharmaceuticals is a biopharmaceutical company that develops and commercializes innovative therapies for psychiatric, sleep, immunological, and other serious medical conditions, leveraging expertise in genetics, genomics, and pharmacogenetics. The company's commercial portfolio includes four FDA-approved products—Fanapt® for schizophrenia and bipolar I disorder, HETLIOZ® for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome, PONVORY® for multiple sclerosis, and NEREUS™ for motion-induced vomiting—which are marketed primarily in the United States and select international markets. Revenue derives from product sales through specialty pharmacies, distributors, and wholesalers, while the company operates a virtual supply chain by contracting with third-party manufacturers for drug production, distribution, and related services rather than operating its own facilities.